Determination of the Relationship Between Serum Uric Blood Levels and the Severity of Coronary Artery Disease in Angiography of Patients with Acute Coronary Syndrome

Mohsen Maadani 1, Mohammad Ali Sadrameli 1, Sami Samiei Amlashi 1, Mohammadreza Hashemimanesh 1, Mostafa Moomivand 1, Fariba Rajabi 1, Mohammad Fallah Anboohi 1, Ali Ghasemi 1 and Jalil Golshani Monfared 1

1Rajaee Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran

Abstract

Background: Uric acid as an inflammatory marker has been hypothesized as a precursor of atherosclerosis and its role has been evaluated in recent studies.

Objectives: In our study we wanted to assess its effect on the severity and extent of coronary artery disease in patients presenting to emergency department with acute coronary syndrome.

Methods: In this cross-sectional descriptive study, we enrolled all patients with ACS who attended to Shahid Rajaie Emergency Department from May 2016 to May 2018. All patients were sampled for their laboratory evaluation of serum uric acid and routine other lab tests. Besides, their traditional risk factors and medications were recorded and all patients underwent coronary angiography while their SYNTAX score was measured.

Results: Two-hundred and six patients were included in our study in which 153 were male (74.3%) and the rest were female (25.7%). The mean age of all patients was 58.37 ± 10.48. From all traditional CAD risk factors, only hyperlipidemia had a direct relation with hyperuricemia (P value < 0.001). Inverse relation was demonstrated between LVEF and serum uric acid level (correlation coefficient -0.126 and P value = 0.047). Analysis also proved a strong relationship between the number of vessels involved and serum uric acid level and the higher serum uric acid level, the more vessels were involved (in SVD 5.29 ± 1.42 mg/dL, 2VD 5.81 ± 162 mg/dL, 3VD 6.14 ± 1.06 mg/dL and 3VD + LM 6.63 ± 1.70 mg/dL and P value = 0.004). Consequently, there was a significant relation between serum uric acid level and SYNTAX score (hyperuricemia prevalence in patients with SYNTAX score less than 22 was 15.8%, in the group of 22 - 32 SYNTAX score 28.6% and in patients with more than 32 SYNTAX score was 41.4% with P value = 0.007).

Conclusions: Serum uric acid level measurement in patients presenting with acute coronary syndrome is both sensitive and efficient and could help in determining the patients’ general probability of atherosclerotic disease.

Keywords: Serum Uric Acid, Coronary Artery Disease, Angiography, SYNTAX Score

1. Background

Uric acid is the terminal product of xanthine oxidase which destruct purine into uric acid. As previous studies have proved, xanthine oxidase also acts as an enzyme to produce reactive oxygen species with its abnormal isotype with consequently injurious effects (1-4). It is also hypothesized that in its destructive pathway, uric acid production has a relation to the antioxidant activity and this reciprocal impact impresses many coincidental benefits (5). Besides these oxidant and antioxidant activities, hyperuricemia has been accused of having a role in hypertension, activation of renin-angiotensin-aldosterone pathway, hypertrophy of vascular tree smooth muscle, renal artery atherosclerosis, ischemic stroke, and heart failure (5-10).

Hyperuricemia showed convincing effects in coronary artery disease and it has been an independent risk factor for higher cardiovascular mortality where every 1 mg/dL increase in uric acid from normal range was associated with 48% higher cardiovascular events (11-14).
tion to demographic and other major coronary artery disease risk factors.

3. Methods

This is a cross-sectional descriptive study conducted in Shahid Rajaie Heart Center Emergency Department (ED). All patients presenting with acute coronary syndrome to ED, 30 to 70 years old from May 2016 to May 2018 were included in this study and patients with known coronary artery disease, renal or hepatic disease, heart failure, malignancies, alcoholics, patients with past use of diuretics and multivitamin supplements were excluded.

Patients were evaluated with their demographic measures, their past history of cardiac disease, medications and major coronary artery disease risk factors. Then they were divided into two groups of patients with normal serum uric acid and hyperuricemia (more than 7 mg/dL and 6 mg/dL in men and women respectively) according to their baseline serum uric acid level. Accordingly, patients underwent coronary artery catheterization from their right femoral artery and their disease severity was assessed by SYNTAX score and the severity was reviewed based on the uric acid level and other considerable determinants. All preliminary lab tests in patients with ACS also were sampled and they are summarized in Table 1.

- Mean LVEF measured by transthoracic echocardiography was 43 ± 8.52. Mean serum uric acid level was 5.77 ± 1.58 mg/dL and hyperuricemia was detected in 30.2% of women and 20.9% of men which showed an insignificant difference (P value = 0.169).

In accordance with the latest ACS definition, patients with STEMI were 50 out of 206 patients (24.3%), NSTEMI in 72 patients (35%) and patients presenting with unstable angina were reported in 84 patients (40.8%). In Table 2, patients were categorized based on SYNTAX score and their coronary artery disease severity and number of vessels involved.

Inverse relation was demonstrated between LVEF and serum uric acid level (correlation coefficient -0.126 and P value = 0.047). Serum uric acid level in all groups of patients was at 5.84 ± 1.43 mg/dl in STEMI group, 5.96 ± 1.83 mg/dL in NSTEMI, 5.57 ± 1.42 mg/dL in unstable angina group and there was no significant difference (P value = 0.287). Analysis also proved a strong relationship between the number of vessels involved and serum uric acid level and higher serum uric acid level was associated with more vessels involved (in SVD 5.29 ± 1.42 mg/dl, 2VD 5.81 ± 162 mg/dL, 3VD 6.14 ± 1.06 mg/dL and 3VD + LM 6.63 ± 1.70 mg/dL and P value = 0.004) in Table 3.

| Table 1. Gender Distribution and Laboratory Assessment |
| Variable | Value* |
|----------|--------|
| Mean age | 57.37 ± 10.48 |
| Men      | 153 (74.3) |
| Women    | 53 (25.7) |
| Diabetic patients | 133 (64.6) |
| Hypertensive patients | 115 (55.8) |
| Dyslipidemia | 117 (56.8) |
| History of cigarette smoking | 129 (62.6) |
| Family history of CAD | 153 (74.3) |
| Serum Hg, mg/dL | 14.01 ± 1.49 |
| WBC      | 8234 ± 2959 |
| Platelet | 225786 ± 53929 |
| BUN      | 16.83 ± 5.68 |
| Cr. mg/dL | 1 ± 0.22 |
| FBS, mg/dL | 152 ± 55.20 |
| AST      | 47.81 ± 2.21 |
| ALT, mg/dL | 37.92 ± 2.03 |
| ALK P    | 206.33 ± 79.16 |
| Bilirubin, mg/dL | 0.77 ± 0.32 |
| LVEF     | 43 ± 8.52 |
| Uric acid | 5.77 ± 1.58 |

* Values are expressed as mean ± SD or No. (%).

In accordance with the latest ACS definition, patients with STEMI were 50 out of 206 patients (24.3%), NSTEMI in 72 patients (35%) and patients presenting with unstable angina were reported in 84 patients (40.8%). In Table 2, patients were categorized based on SYNTAX score and their coronary artery disease severity and number of vessels involved.

Table 2. Gender Distribution and Laboratory Assessment

| Variable          | Value* |
|-------------------|--------|
| Mean age          | 57.37 ± 10.48 |
| Men               | 153 (74.3) |
| Women             | 53 (25.7) |
| Diabetic patients | 133 (64.6) |
| Hypertensive patients | 115 (55.8) |
| Dyslipidemia      | 117 (56.8) |
| History of cigarette smoking | 129 (62.6) |
| Family history of CAD | 153 (74.3) |
| Serum Hg, mg/dL   | 14.01 ± 1.49 |
| WBC               | 8234 ± 2959 |
| Platelet          | 225786 ± 53929 |
| BUN               | 16.83 ± 5.68 |
| Cr. mg/dL         | 1 ± 0.22 |
| FBS, mg/dL        | 152 ± 55.20 |
| AST               | 47.81 ± 2.21 |
| ALT, mg/dL        | 37.92 ± 2.03 |
| ALK P             | 206.33 ± 79.16 |
| Bilirubin, mg/dL  | 0.77 ± 0.32 |
| LVEF              | 43 ± 8.52 |
| Uric acid         | 5.77 ± 1.58 |

* Values are expressed as mean ± SD or No. (%).
Table 2. Patients’ Presenting Pattern of CAD

| Variable                  | No. (%)   |
|---------------------------|-----------|
| STEMI                     | 50 (24.3) |
| NSTEMI                    | 72 (35)   |
| Unstable angina           | 84 (40.8) |
| SVD                       | 70 (34)   |
| 2VD                       | 69 (33.5) |
| 3VD                       | 55 (26.7) |
| 3VD + LM                  | 12 (5.8)  |
| SYNTAX less than 22       | 114 (55.3)|
| SYNTAX 22 - 32            | 63 (30.6) |
| SYNTAX more than 32       | 29 (14.1) |

Table 3. Association of Serum Uric Acid Level and Severity of Coronary Artery Disease

| Variable                      | Serum Uric Acid Level | P Value |
|-------------------------------|-----------------------|---------|
| ACS subgroup                  |                       | 0.2     |
| STEMI                         | 5.84 ± 1.43           |         |
| NSTEMI                        | 5.96 ± 1.43           |         |
| Unstable angina               | 5.57 ± 1.42           |         |
| Coronary artery disease       |                       | 0.004   |
| SVD                           | 5.29 ± 1.42           |         |
| 2VD                           | 5.81 ± 1.62           |         |
| 3VD                           | 6.14 ± 1.56           |         |
| Left main lesion              | 6.63 ± 1.70           |         |
| Severity of coronary disease  |                       | 0.003   |
| SYNTAX score < 22             | 5.45 ± 1.35           |         |
| 22 < SYNTAX score < 32        | 6.06 ± 1.77           |         |
| 32 < SYNTAX score             | 6.40 ± 1.75           |         |

All other laboratory and major coronary artery disease risk factors were evaluated to find out uric acid level change in each category and the only significant parameter which proved to be associated with was hyperlipidemia (P value less than 0.001 in patients with concomitant hyperuricemia). Hence, no meaningful P value was detected in diabetes patients, in patients with a history of cigarette smoking, hypertension and none of the laboratory test sampled from patients were related to hyperuricemia.

Receiver operating characteristics (ROC) curve also demonstrated acceptable effect of uric acid in predicting extensive CAD with or without involvement of LM disease (P value = 0.018 and area under the curve was 0.638). Best threshold for uric acid level to predict 3VD was serum level of 5.45 which execute sensitivity and specificity of 70% and 50% respectively. Besides, serum uric acid level of 5.65 was the best threshold to foreseen the SYNTAX score of more than 32 with a sensitivity of 65% and specificity of 51% (Figures 1 and 2).
5. Discussion

Previous studies have disclosed the role of uric acid in atherosclerosis but the precise mechanism is still unknown. The impact of uric acid on myocardial hypertrophy, ROS production and destruction, endothelial dysfunction and platelet aggregation, have all been speculated formerly. In our study, we determined serum uric acid level in patients presenting with acute coronary syndrome could prognosticate extensive atherosclerotic disease and would help in deciding preferred patients' probability of revascularization modality based on their serum uric acid which is fast and easy to measure. We also evaluated other laboratory parameters with probable role in atherosclerosis to define uric acid effect in more details.

The second intriguing verdict was significant association of higher serum uric acid level with patients' SYNTAX score. In ED we measured uric acid level and then all patients underwent coronary catheterization to define their SYNTAX score. Eslami et al. also showed a meaningful relation between serum uric acid level and CAD and the mean uric acid level in patients with CAD was 7.62 ± 1.07 mg/dL. In their study, patients with chronic kidney disease were also included but we decided to exclude them in favor of diminishing conflicting results (15). Other chronic inflammatory diseases were excluded from our study. Nabati et al. discerned that higher uric acid level is an independent risk for extensive CAD which was compatible with our conclusion (16). This pro-atherosclerotic effect was also noticeable with omitting other known involving factors. In this study, patients with hyperuricemia had more coronary risk factors, lower serum HDL, higher serum Cr level, and they also had lower LVEF compared to their control group (17). The only laboratory marker in this study which had a meaningful relation to serum uric acid was total cholesterol level. In a study done by Andrikou et al., it was evinced that hyperuricemia with involvement of hypertension can lead to development of coronary artery disease but the role of hypertension was not meaningful in our study (18). Accordingly, the role of hyperuricemia would be independent of known coronary risk factors and its role in development and progression of atherosclerosis is inevitable.

5.1. Conclusions

This article showed significant association of higher serum uric acid level with patients' SYNTAX score.

Footnotes

**Authors' Contribution:** All steps of this study was admitted by Medical Ethics Committee of Shahid Rajaie Heart Center and no extra cost was charged from the patients in order to fulfill the measured data.

**Conflict of Interests:** None declared.

**Ethical Considerations:** Ethics code: IR.IUMS.FMD.REC 1396.9311171018.

**Funding/Support:** None declared.

**References**

1. Kang DH, Ha SK. Uric acid puzzle: Dual role as antioxidand pro-oxidant. *Electrolyte Blood Press. 2014;12(1):3-6. doi: 10.5049/EBP.2014.12.11.* [PubMed: 25061467]. [PubMed Central: PMC4053844].

2. Glantouzis GK, Tsimoyiannis EC, Kappas AM, Galaris DA. Uric acid and oxidative stress. *Curr Pharm Des. 2005;11(32):4145-51. doi: 10.2174/1389450410051103241451.* [PubMed: 16375730].

3. Ting WS, Webb DJ, Maxwell SR. Systemic uric acid administration increases serum antioxidant capacity in healthy volunteers. *J Cardiovasc Pharmacol. 2003;38(3):365-71. doi: 10.1097/00004836-200309000-00010.* [PubMed: 14186241].

4. George J, Carr E, Davies J, Belch JJ, Struthers A. High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid. *Circulation. 2006;114(25):2508-16. doi: 10.1161/CIRCULATIONAHA.106.651117.* [PubMed: 17180341].

5. Sanchez-Lozada LG, Tapia E, Soto V, Avila-Casado C, Franco M, Zhao L, et al. Treatment with the xanthine oxidase inhibitor febuxostat lowers uric acid and alleviates systemic and glomerular hypertension in experimental hyperuricaemia. *Nephrol Dial Transplant. 2008;23(4):1179-85. doi: 10.1093/ndt/gfm783. doi: 10.1093/ndt/gfm783.* [PubMed: 18048425].

6. Borghi C, Rosci EA, Bardin T, Dawson J, Dominiczak A, Kielstein JT, et al. Serum uric acid and the risk of cardiovascular and renal disease. *J Hypertens. 2015;33(9):1729-41. discussion 1741. doi: 10.1097/HJH.0000000000000701. doi: 10.1097/HJH.0000000000000701.* [PubMed: 26136207].

7. Haig A. On uric acid and arterial tension. *Br Med J. 1889;3(467):288-91. doi: 10.1136/bmj.3.467.288.* [PubMed: 20752582]. [PubMed Central: PMC2544774].

8. Niskanen LK, Laaksonen DE, Nyyssonen K, Alfthan G, Lakka HM, Lakka TA, et al. Uric acid level as a risk factor for cardiovascular and all-cause mortality in middle-aged men: A prospective cohort study. *Arch Intern Med. 2004;164(14):1546-51. doi: 10.1001/archinte.164.14.1546.* [PubMed: 15272287].

9. Khanna D, Fitzgerlad JD, Khanna PP, Bae S, Singh MK, Neogi T, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: Systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. *Arthritis Care Res (Hoboken). 2012;64(10):1431-46. doi: 10.1002acr.21772. doi: 10.1002/acr.21772.* [PubMed: 23024028]. [PubMed Central: PMC3683400].

10. Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. *N Engl J Med. 2008;359(7):781-2. doi: 10.1056/NEJMra0800885. doi: 10.1056/NEJMra0800885.* [PubMed: 18946066]. [PubMed Central: PMC2684310].

11. Abbott RD, Brand FN, Kannel WB, Castelli WP. Gout and coronary heart disease: The Framingham study. *J Clin Epidemiol. 1988;41(3):237-42. doi: 10.1016/0895-4356(88)90127-8.*

12. Lottmann K, Chen X, Schadlich PK. Association between gout and all-cause as well as cardiovascular mortality: A systematic review. *Curr Rheumatol Rep. 2012;14(2):195-203. doi: 10.1007/s11926-011-0234-2.* [PubMed: 22350606]. [PubMed Central: PMC3297741].

13. Freedman DS, Williamson DF, Gunter EW, Byers T. Relation of serum uric acid to mortality and ischemic heart disease. *The NHANES I epidemiologic follow-up study. Am J Epidemiol. 1995;141(7):637-44. doi: 10.1093/aje/141.7.637.* [PubMed: 7702038].

14. Bos MJ, Koudstaal PJ, Hofman A, Wittreman JC, Breteler MM. Uric acid is a risk factor for myocardial infarction and
stroke: The Rotterdam study. Stroke. 2006;37(6):1503-7. doi: 10.1161/01.STR.0000221716.55088.d4. [PubMed: 16675740].

15. Nabati M, Shiran M, Esfahani Z, Yousefnejad K, Habibi V, Dabirian M, et al. [Relationship between the level of serum uric acid and severity of coronary artery atherosclerosis determined by coronary angiography in patients with chronic stable angina]. J Mazandaran Univ Med Sci. 2013;22(98):19-26. Persian.

16. Karimian B, Khademvatan K, Seyyed-Mohammadzad MH, Alinejad V, Abasnejad P, Noori F, et al. [Evaluation of the associations between the severity of coronary heart disease and serum levels of uric acid or fetuin-a undergoing coronary angiography]. J Urmia Univ Med Sci. 2015;26(8):663-7. Persian.

17. Tasic I, Kostic S, Stojanovic NM, Skakic V, Cvetkovic J, Djordjevic A, et al. Significance of asymptomatic hyperuricemia in patients after coronary events. Scand J Clin Lab Invest. 2018;78(4):312-7. doi: 10.1080/00365513.2018.1467035. [PubMed: 29703085].

18. Andrikou I, Tsiofis C, Dimitriadis K, Konstantinidis D, Kastakogias A, Kouroumet M, et al. Uric acid as an independent predictor of coronary artery disease in essential hypertension: Data from an 8-year-follow-up study. Clin Exp Pharmacol Physiol. 2018;45(8):866-9. doi: 10.1111/1440-1681.12928. [PubMed: 29489034].